Journals / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 1

Does dutasteride have any cardioprotective effect in elderly men? A prospective randomised controled study

Pages
237–242
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Additionally, echocardiographic parameters, carotid intima-media thickness and brachial artery RI were alsosimilar.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To investigate whether the increased serum levels of testosterone secondary to Dutasteride therapy has any protective effecton cardiovascular system.Material and Methods: A prospective analysis of 50 patients diagnosed benign prostatic enlargement between May 2015 and May2017 was performed.
📊
Key Findings & Data:After randomization 25 patients treated with daily administration of 0.5 mg dutasteride (Dutasteride Group),and 25 patients were not given dutasteride (Control Group).
💡
Conclusion & Impact:Additionally, echocardiographic parameters, carotid intima-media thickness and brachial artery RI were alsosimilar.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: To investigate whether the increased serum levels of testosterone secondary to Dutasteride therapy has any protective effecton cardiovascular system.Material and Methods: A prospective analysis of 50 patients diagnosed benign prostatic enlargement between May 2015 and May2017 was performed. After randomization 25 patients treated with daily administration of 0.5 mg dutasteride (Dutasteride Group),and 25 patients were not given dutasteride (Control Group). We analyzed some serum novel cardiaovascular marker levels at baselineand after 6 months of the treatment. Echocardiography, carotid intima-media thickness and brachial artery resistive index (RI) wereevaluated at baseline and after 6 months of the treatment.Statistical analyses were performed using SPSS, version 21. While “t test” was used for comparison the independent groups, pairedt test was used in the matched groups. Statistical significance was considered at p0.05). Additionally,echocardiographic parameters, carotid intima-media thickness and brachial artery RI were similar before and after dutasteridetratment.Conclusion: After the short-term use of dutasteride, there was not a statistically significant difference in serum Lp a, hs-CRP andNT-proBNP levels. Additionally, echocardiographic parameters, carotid intima-media thickness and brachial artery RI were alsosimilar.

🔖

Cite This Article

ÖĞREDEN, E., BAŞER, B., KARAGÖZ, E., OĞUZ, U., KARAGÖZ, A., TOSUN, A., DEMİRELLİ, E., USTA, M., KARADAYI, M., KÖSEOĞLU, M. H., YALÇIN, O. (2022). Does dutasteride have any cardioprotective effect in elderly men? A prospective randomised controled study. Annals of Medical Research, Cilt: 27 - Sayı: 1, 237–242. https://ajindex.com/articles/446154

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Armeni E, Lambrinoudaki I. Androgens and cardiovascular disease in women and men. Maturitas 2017;104:54-72
  2. Souverein PC, Herings RM, De la Rosette JJ, et al. Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations. J Clin Epidemiol 2001;54:518-24
  3. Chasland LC, Knuiman MW, Divitini ML, et al. Greater physical activity and higher androgen concentrations are independently associated with lower cardiometabolic risk in men. Clin Endocrinol (Oxf). 2017;87:466-74
  4. Traish AM, Haider A, Haider KS, et al. Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups. J Cardiovasc Pharmacol Ther. 2017;22:414-33
  5. Pritchard CC, Nelson PS. Gene expression profiling in the developing prostate. Differentiation 2008;76:624- 40
  6. Chou CH, Lin CL, Lin MC, et al. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia. J Endocrinol Invest 2015;38:799-805
  7. Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829-36
  8. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014;9:85805
  9. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol 2011;58:1674-81
  10. Carson CC, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med 2012;9:54-67
  11. Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706-15
  12. Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010;56:1310-6
  13. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baro